NASDAQ:MRTX - Mirati Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $74.75 +2.97 (+4.14 %) (As of 02/20/2019 12:25 PM ET)Previous Close$71.78Today's Range$72.13 - $75.2152-Week Range$24.65 - $76.00Volume10,178 shsAverage Volume484,590 shsMarket Capitalization$2.57 billionP/E Ratio-26.76Dividend YieldN/ABeta2.14 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; Array BioPharma, Inc.; and Bristol-Myers Squibb Company to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California. Receive MRTX News and Ratings via Email Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRTX Previous Symbol CUSIPN/A Webwww.mirati.com Phone858-332-3410Debt Debt-to-Equity RatioN/A Current Ratio11.22 Quick Ratio11.22Price-To-Earnings Trailing P/E Ratio-26.76 Forward P/E Ratio-23.96 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book14.08Profitability EPS (Most Recent Fiscal Year)($2.78) Net Income$-70,420,000.00 Net MarginsN/A Return on Equity-46.80% Return on Assets-42.71%Miscellaneous Employees51 Outstanding Shares34,370,000Market Cap$2.57 billion OptionableOptionable Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions What is Mirati Therapeutics' stock symbol? Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX." How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics Inc (NASDAQ:MRTX) released its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.87) by $0.02. View Mirati Therapeutics' Earnings History. When is Mirati Therapeutics' next earnings date? Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Mirati Therapeutics. What price target have analysts set for MRTX? 11 brokers have issued 1-year target prices for Mirati Therapeutics' stock. Their predictions range from $37.00 to $85.00. On average, they anticipate Mirati Therapeutics' share price to reach $60.00 in the next year. This suggests that the stock has a possible downside of 19.9%. View Analyst Price Targets for Mirati Therapeutics. What is the consensus analysts' recommendation for Mirati Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics. What are Wall Street analysts saying about Mirati Therapeutics stock? Here are some recent quotes from research analysts about Mirati Therapeutics stock: 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (1/15/2019) 2. HC Wainwright analysts commented, "We derive our $65 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for sitravatinib and mocetinostat. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 15% POS for mocetinostat, our YE2018 fully diluted net cash estimate of $4.79/share, and we value the early stage pipeline at $5.38/ share to arrive at our price target. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (11/12/2018) Has Mirati Therapeutics been receiving favorable news coverage? Headlines about MRTX stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mirati Therapeutics earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Mirati Therapeutics' key competitors? Some companies that are related to Mirati Therapeutics include Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN). Who are Mirati Therapeutics' key executives? Mirati Therapeutics' management team includes the folowing people: Dr. Rodney W. Lappe, Exec. Chairman (Age 64)Dr. Charles M. Baum, Pres, CEO & Director (Age 61)Dr. James Christensen, Chief Scientific Officer (Age 51)Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44) Who are Mirati Therapeutics' major shareholders? Mirati Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.97%), Jennison Associates LLC (3.54%), Geode Capital Management LLC (0.91%), Northern Trust Corp (0.80%), Amundi Pioneer Asset Management Inc. (0.78%) and Lord Abbett & CO. LLC (0.78%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics. Which institutional investors are selling Mirati Therapeutics stock? MRTX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Broadfin Capital LLC, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, MetLife Investment Advisors LLC, Virtus ETF Advisers LLC, New York State Common Retirement Fund and Bellevue Group AG. Company insiders that have sold Mirati Therapeutics company stock in the last year include Aaron I Davis, Boxer Capital, Llc, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio and Jamie Christensen. View Insider Buying and Selling for Mirati Therapeutics. Which institutional investors are buying Mirati Therapeutics stock? MRTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Perceptive Advisors LLC, Rhenman & Partners Asset Management AB, Amundi Pioneer Asset Management Inc., RTW Investments LP, Squarepoint Ops LLC and Geode Capital Management LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics. How do I buy shares of Mirati Therapeutics? Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mirati Therapeutics' stock price today? One share of MRTX stock can currently be purchased for approximately $74.95. How big of a company is Mirati Therapeutics? Mirati Therapeutics has a market capitalization of $2.58 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe. What is Mirati Therapeutics' official website? The official website for Mirati Therapeutics is http://www.mirati.com. How can I contact Mirati Therapeutics? Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected] MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 315 (Vote Outperform)Underperform Votes: 216 (Vote Underperform)Total Votes: 531MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: What is Depreciation?